盐酸西替利嗪滴剂联合孟鲁司特钠咀嚼片治疗儿童咳嗽变异性哮喘的临床研究

目的 观察盐酸西替利嗪滴剂联合孟鲁司特钠咀嚼片治疗儿童咳嗽变异性哮喘(CVA)的临床疗效及安全性.方法 将110例CVA患儿随机分为对照组和试验组,每组55例.对照组给予孟鲁司特钠咀嚼片,3～6岁每次4 mg,qd,6～12岁每次5 mg,qd,每晚顿服;试验组在对照组治疗的基础上,给予盐酸西替利嗪滴剂,3～6岁每次0...

Clinical trial of cetirizine dihydrochloride oral drops combined with montelukast sodium chewable tablets in the treatment of children with cough variant asthma

Objective To observe the clinical efficacy and safety of cetirizine dihydrochloride oral drops combined with montelukast sodium chewable tablets in the treatment of children with cough variant asthma(CVA). Methods A total of one hundred and ten children with CVA were randomly divided into control and treatment groups with 55 cases per group. The control group was given montelukast sodium chewable tablets 4 mg(3-6 years old) or 5 mg(6-12 years old) per time, qd, orally, once every night. The treatment group was given cetirizine dihydrochloride oral drops 0.25 mL(3-6 years old) or 0.5 mL(6-12 years old) per time, bid, orally, based on the control group. Two groups were treated for 3 months. The clinical efficacy, lung function and adverse drug reactions were compared between two groups. Results After treatment, the total effective rates of treatment and control groups were 90.91%(50 cases/55 cases) and 74.55%(41 cases/55 cases) with significant difference(P<0.05). After treatment, the main indexes of treatment and control groups were compared: the forced expiratory volume in one second was( 3. 06 ± 0. 51)and( 2. 35 ± 0. 37) L,forced vital capacity was( 5. 15 ± 1. 27) and( 4. 02 ± 1. 06) L,the differences were statistically significant( all P < 0. 05). The adverse drug reactions of the treatment group were headache,drowsiness,dry mouth and diarrhea,which in the control group were drowsiness,dry mouth and dizziness. The incidences of total adverse drug reactions in the treatment and control groups were 7. 27% and 9. 09% without significant difference( P > 0. 05).Conclusion Cetirizine dihydrochloride oral drops combined with montelukast sodium chewable tablets have a definitive clinical efficacy in the treatment of children with CVA,which can significantly improve the lung function,without increasing the incidence of adverse drug reactions.